CF-Emerging therapies: Modulation inflammation

Paediatric Respiratory Reviews

Volumn 7, Issue SUPPL. 1, 2006, Pages

  Fayon, M ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

child; cystic fibrosis; inflammation; therapeutics

Indexed keywords

ACETYLCYSTEINE; ALPHA 1 ANTITRYPSIN; ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; AZITHROMYCIN; BRONCHODILATING AGENT; CORTICOSTEROID; CYTOKINE ANTIBODY; DEPELESTAT; DORNASE ALFA; FISH OIL; GAMMA1B INTERFERON; IBUPROFEN; INTERLEUKIN 10; LEUKOCYTE ELASTASE; LEUKOCYTE ELASTASE INHIBITOR; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR AFFECTING AGENT; MACROLIDE; MONTELUKAST; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PLACEBO; RETINOL; SODIUM CHLORIDE; STEROID; TECHNETIUM 99M; TOBRAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CATARACT; CLINICAL TRIAL; CYSTIC FIBROSIS; DISEASE COURSE; DISEASE EXACERBATION; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LOW DRUG DOSE; LUNG DISEASE; LUNG INJURY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW;

ACETYLCYSTEINE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRONCHITIS; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; FREE RADICAL SCAVENGERS; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; PANCREATIC ELASTASE; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 33745485358     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2006.04.212     Document Type: Review

References (43)

1. Armstrong D. Evidence for pulmonary inflammation and infection in asymptomatic cystic fibrosis infants and children. Pediatr Pulmonol 28s (2005) 162-163
2. Balfour-Lynn I.M., et al. CF WISE-multicentre randomised controlled trial of withdrawal of inhaled corticosteroids. Pediatr Pulmonol 28s (2005) 123-124
3. Khan T.Z., et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151 (1995) 1075-1082
4. Rosenfeld M., et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 32 (2001) 356-366
5. Puchelle E., et al. Airway mucus in cystic fibrosis. Paediatr Respir Rev 3 (2002) 115-119
6. Smyth R.L., et al. Consequences of viral infection in the lung: observations from the clinic and the bench. Pediatr pulmonol 28s (2005) 147-148
7. Armstrong D.S., et al. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol 40 (2005) 500-510
8. da Silva M.C., et al. Dynamic interaction between airway epithelial cells and Staphylococcus aureus. Am J Physiol Lung Cell Mol Physiol 287 (2004) L543-L551
9. Gutierrez J.P., et al. Interlobar differences in bronchoalveolar lavage fluid from children with cystic fibrosis. Eur Respir J 17 (2001) 281-286
10. Nick J.A. Neutrophil-mediated inflammation in the CF airway: Mechanisms of injury and potential therapeutic strategies. Pediatr Pulmonol 28s (2005) 120-122
11. Courtney J.M., et al. Cytokines and inflammatory mediators in cystic fibrosis. J Cyst Fibros 3 (2004) 223-231
12. Street M.E., et al. Inflammation is a modulator of the insulin-like growth factor (IGF)/IGF-binding protein system inducing reduced bioactivity of IGFs in cystic fibrosis. Eur J Endocrinol 154 (2006) 47-52
13. Witko-Sarsat V., et al. Disturbed myeloperoxidase-dependent activity of neutrophils in cystic fibrosis homozygotes and heterozygotes, and its correction by amiloride. J Immunol 157 (1996) 2728-2735
14. Grasemann H., et al. Increased arginase activity in cystic fibrosis airways. Am J Respir Crit Care Med 172 (2005) 1523-1528
15. Geddes D. Inflammation: Defense or offense. Pediatr Pulmonol 28s (2005) 122-123
16. Dinwiddie R. Anti-inflammatory therapy in cystic fibrosis. J Cyst Fibros 4 Suppl 2 (2005) 45-48
17. Elkins M.R., et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 354 (2006) 229-240
18. Shinkai M., et al. Macrolides and airway inflammation in children. Paediatr Respir Rev 6 (2005) 227-235
19. Clément A., et al. Long-term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatr Pulmonol 28s (2005) 276A
20. Colombo C., et al. Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. Pediatr Pulmonol 40 (2005) 15-21
21. Gibson R.L., et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 167 (2003) 841-849
22. Ordonez C.L., et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 168 (2003) 1471-1475
23. Sagel S.D. Sputum biomarkers in cystic fibrosis clinical trials. Pediatr Pulmonol 28s (2005) 171-172
24. Konstan M.W., et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 332 (1995) 848-854
25. Cheng K, et al. Oral steroids for cystic fibrosis. Cochrane Database Syst Rev 2000 CD000407.
26. Dezateux C, et al. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev 2000 CD001915.
27. Démographiques INdE, et al. Rapport de la situation de la mucoviscidose en France en 2002-2003; 2003 p. 128.
28. Konstan M.W., et al. Results of a phase II clinical trial of BIIL 248 BS (an LTB4 receptor antagonist) for the treatment of CF lung disease. Pediatr Pulmonol 28s (2005) 125-126
29. Graff G.R., et al. Montelukast pharmacokinetics in cystic fibrosis. J Pediatr 142 (2003) 53-56
30. Schmitt-Grohe S., et al. Leukotriene receptor antagonists in children with cystic fibrosis lung disease: anti-inflammatory and clinical effects. Paediatr Drugs 7 (2005) 353-363
31. Schmitt-Grohe S., et al. Anti-inflammatory effects of montelukast in mild cystic fibrosis. Ann Allergy Asthma Immunol 89 (2002) 599-605
32. Stelmach I., et al. Effects of montelukast treatment on clinical and inflammatory variables in patients with cystic fibrosis. Ann Allergy Asthma Immunol 95 (2005) 372-380
33. Ratjen F., et al. Dornase alpha in pediatric CF patients with normal lung function - effect of airway inflammation. Pediatr Pulmonol 28s (2005) 143-144
34. Ratjen F., et al. DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha. Pediatr Pulmonol 39 (2005) 1-4
35. Tirouvanziam R., et al. High-dose N-acetylcysteine as a systemic anti-oxidant and potent inhibitor of lung inflammation in CF: A pilot phase 1 trail. Pediatr Pulmonol 28s (2005) A214
36. Bines J.E., et al. Vitamin A and E deficiency and lung disease in infants with cystic fibrosis. J Paediatr Child Health 41 (2005) 663-668
37. Durieu I., et al. Effect of an intravenus fish oil emulsion enriched in n-3 fatty acids on blood cells and plasma fatty acid composition: a pilot study. Pediatr pulmonol 27s (2004) A408
38. Martin S.L., et al. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol 41 (2006) 177-183
39. Saudubray F., et al. Phase IIa clinical study of a new human neutrophil elastase inhibitor (hNE), EPI hNE4 (DX-890), with repeated administration by inhalation in adult cystic fibrosis patients. J Cyst Fibros 2 (2003) A85
40. de Monte M., et al. Inhaled human neutrophil elastase inhibitor EPI hNE4 (DX-890) in adult cystic fibrosis patients. International society of aerosols in medicine15th international congress. March (Perth, Australia) (2005)
41. Chmiel J.F., et al. Anti-inflammatory medications for cystic fibrosis lung disease: selecting the most appropriate agent. Treat Respir Med 4 (2005) 255-273
42. Moss R.B., et al. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr Pulmonol 39 (2005) 209-218
43. Prescott Jr. W.A., et al. Antiinflammatory therapies for cystic fibrosis: past, present, and future. Pharmacotherapy 25 (2005) 555-573